Interview with Andrew Giddy, CEO, Nucleus Network
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
Address: 5th Floor, Burnet Tower, AMREP Precinct ,89 Commercial Road,Melbourne, Victoria, Australia, 3004
Tel: + 613 9076 8900
Web: http://www.nucleusnetwork.com.au/page.aspx?54
Nucleus Network is committed to operational and service excellence. All Nucleus Network’s clinical research is conducted in accordance with internationallyrecognised standards of Good Clinical Practice. Data generated is accepted by all major regulatory jurisdictions including FDA, EMEA and TGA.
Whether you work with Nucleus Network clinical research team, education or consulting personnel, Nucleus Network are committed to providing high quality services and adherence to ethical principles. It is Nucleus Network’s aim to deliver services in a timely and cost-effective manner and to give customers peace of mind. To achieve this, Nucleus Network uses the latest technologies within a coordinated and collaborative framework.
Nucleus Network is committed to quality and continuous improvement in order to meet our clients’ needs for timeliness and high quality data.
Research, Clinical trials
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
“Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008.…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
Senior Partner Dr Sree Haran has also participated in this interview. TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would…
The company underwent some landmark changes under your leadership, changing the balance between different pillars of the business – retail, wholesale product delivery, marketing programs. Would you begin by outlining…
After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and…
Can you start by commenting on the state of diabetes in Australia at present? According to 2011 statistics nearly one million Australians have diabetes and about half of those are…
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Would you please introduce The Pharmacy Guild to our readers, giving an insight in its function and its membership? We are the premium body representing community pharmacies in Australia, about…
Earlier this year the company set a crucial step in its internationalization strategy with the acquisition of Ascent. Would you outline the significance of the acquisition within Watson’s global expansion…
We last met you in 2008 as Chair of the Pharmaceuticals Industry Council (PIC), which set itself the goal of doubling the levels of exports, R&D investment, manufacturing, value-added activities,…
Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike…
See our Cookie Privacy Policy Here
